10-Q: Syra Health Q1 2026 Financial Results

Syra Health reports a return to profitability in Q1 2026 with net income of $240,979, driven by growth in population health services.

Summary

• Net revenue for Q1 2026 was $2,273,520, a 22% increase compared to $1,857,774 in Q1 2025.
• Achieved net income of $240,979 for the quarter, compared to a net loss of $472,265 in the prior year period.
• Gross profit margin improved to 43% in Q1 2026 from 32% in Q1 2025.
• Operating expenses decreased significantly to $780,272 from $1,062,490 in Q1 2025 due to cost-cutting measures.
• Cash and cash equivalents increased to $2,922,318 as of March 31, 2026, from $1,614,733 at year-end 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report; while the company achieved a surprise profit and improved margins, the persistent going concern warning and the need for future capital raises temper the positive financial results.

Positives

• Achieved profitability with net income of $240,979.
• Revenue growth of 22% year-over-year.
• Significant improvement in gross profit margins (43% vs 32%).
• Successful reduction in operating expenses by 27% year-over-year.
• Strong cash position of $2.92 million.

Negatives

• Healthcare workforce revenue declined by $142,215 year-over-year.
• Heavy reliance on government contracts, specifically the Indiana FSSA, which accounted for 20% of revenue.
• Accumulated deficit remains high at $9,479,547.
• Significant concentration risk with Humana, Inc. accounting for 21% of accounts receivable.

Risks

• Substantial doubt regarding the ability to continue as a going concern due to early-stage development and potential funding needs.
• Dependence on state and federal government budgets which are subject to spending pauses or cancellations.
• Need to raise additional capital to fund operations for the next twelve months.
• Potential for contract penalties for non-performance or ethical violations.
• Reliance on a limited number of customers for a significant portion of revenue and accounts receivable.

Future Outlook

The company expects to continue pursuing additional capital through debt or equity financing to sustain operations. Management notes that federal and state budget reviews may lead to delays or cancellations in contract awards, which could negatively impact future revenue and cash flows.

Management Comments

• Management believes that existing liquidity will not be sufficient to fund operations for the next twelve months.
• The company is focused on streamlining operations by reducing redundancies and optimizing the workforce.
• Management intends to replicate current projects with similar customers across the country to drive growth.

Industry Context

StockSavvy.ai notes that Syra Health operates in a highly competitive healthcare services market, where profitability is often challenged by high customer concentration and reliance on government funding. The shift toward project-based population health services is a common industry trend to improve margins.

Comparison to Industry Standards

• The company's reliance on government contracts (FSSA) is typical for smaller healthcare service providers but presents higher volatility compared to diversified large-cap healthcare firms.
• The 43% gross margin is competitive for staffing-heavy models, reflecting a successful pivot toward higher-margin consulting and population health services.
• The going concern warning is common for small-cap, early-stage healthcare companies that have not yet achieved consistent positive cash flow.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Related Party Transactions

• Lease agreement with STVentures, LLC for corporate headquarters.
• IT services provided by RAD CUBE LLC.
• Recruitment and HR services provided by NLogix IT Services Private Limited and SKL Demand Private Limited.

Stakeholder Impact

• Shareholders: Potential dilution if additional equity financing is required.
• Employees: Ongoing focus on workforce optimization and cost reduction.
• Creditors: Continued monitoring of liquidity and going concern status.

Next Steps

• Continue to seek additional financing to fund operations.
• Expand sales and business development teams.
• Advance the scientific foundation and AI technology of the Syrenity application.
• Monitor federal and state budget spending for potential contract impacts.

Key Dates

Recommendation

While the company showed strong operational improvement and profitability, the 'going concern' warning and the explicit need for future capital raises suggest significant execution risk, warranting a hold until the company secures long-term funding.

Keywords

Syra Health, Healthcare Services, Population Health, Healthcare Staffing, Digital Health, Mental Health, 10-Q